Ubiquilin-mediated small molecule inhibition of mammalian target of rapamycin complex 1 (mTORC1) signaling

Journal of Biological Chemistry

Volumn 291, Issue 10, 2016, Pages 5221-5233

  Coffey, Rory T ^a   Shi, Yuntao ^a   Long, Marcus J C ^a,b   Marr, Michael T ^a   Hedstrom, Lizbeth ^a  

^a BRANDEIS UNIVERSITY   (United States)

^b Department of Obstetrics Gynecology   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTICS; BINS; CELL CULTURE; DISEASES; MAMMALS; MOLECULES; NEURODEGENERATIVE DISEASES; PHOSPHORYLATION; PROTEINS;

BINDING PROTEINS; CELLULAR METABOLISM; CYTOSOLIC PROTEINS; HUMAN LEUKEMIA CELLS; MASTER REGULATORS; NEURODEGENERATION; REGULATORY PATHWAY; SMALL MOLECULE INHIBITOR;

SIGNALING;

BINDING PROTEIN; CBZ B3A; INITIATION FACTOR 4E BINDING PROTEIN 1; MAMMALIAN TARGET OF RAPAMYCIN COMPLEX 1; MAMMALIAN TARGET OF RAPAMYCIN COMPLEX 2; PROTEIN INHIBITOR; RAPAMYCIN; S6 KINASE; UBIQUILIN 1; UBIQUILIN 2; UBIQUILIN 4; UNCLASSIFIED DRUG; ARGININE; CARBAMIC ACID DERIVATIVE; CBZ-B3A; EIF4EBP1 PROTEIN, HUMAN; ENZYME INHIBITOR; MECHANISTIC TARGET OF RAPAMYCIN COMPLEX 1; MULTIPROTEIN COMPLEX; PHOSPHOPROTEIN; PROTEIN BINDING; SIGNAL TRANSDUCING ADAPTOR PROTEIN; TARGET OF RAPAMYCIN KINASE; UBIQUITIN;

ARTICLE; AUTOPHAGY; CELL GROWTH; CONTROLLED STUDY; DRUG EFFECT; DRUG MECHANISM; DRUG PROTEIN BINDING; EMBRYO; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION; ANALOGS AND DERIVATIVES; ANTAGONISTS AND INHIBITORS; CELL PROLIFERATION; CHEMISTRY; DRUG EFFECTS; GENETICS; HEK293 CELL LINE; METABOLISM; PHOSPHORYLATION; PROTEIN PROCESSING; PROTEIN SYNTHESIS; TUMOR CELL LINE;

ADAPTOR PROTEINS, SIGNAL TRANSDUCING; ARGININE; CARBAMATES; CELL LINE, TUMOR; CELL PROLIFERATION; ENZYME INHIBITORS; HEK293 CELLS; HUMANS; MULTIPROTEIN COMPLEXES; PHOSPHOPROTEINS; PHOSPHORYLATION; PROTEIN BINDING; PROTEIN BIOSYNTHESIS; PROTEIN PROCESSING, POST-TRANSLATIONAL; RIBOSOMAL PROTEIN S6 KINASES; SIGNAL TRANSDUCTION; TOR SERINE-THREONINE KINASES; UBIQUITINS;

EID: 84964619871     PISSN: 00219258     EISSN: 1083351X     Source Type: Journal    
DOI: 10.1074/jbc.M115.691584     Document Type: Article

References (72)

1. Guertin, D. A., and Sabatini, D. M. (2007) Defining the role of mTOR in cancer. Cancer Cell 12, 9-22
2. Briaud, I., and Dickson., L. M., Lingohr, M. K., McCuaig, J. F., and Lawrence., J. C., and Rhodes, C. J. (2005) Insulin receptor substrate-2 proteasomal degradation mediated by a mammalian target of rapamycin (mTOR)-induced negative feedback down-regulates protein kinase B-mediated signaling pathway in beta-cells. J. Biol. Chem. 280, 2282-2293
3. Liu, P., Cheng, H., Roberts, T. M., and Zhao, J. J. (2009) Targeting the phosphoinositide 3-kinase pathway in cancer. Nat. Rev. Drug Discov. 8, 627-644
4. Laplante, M., and Sabatini, D. M. (2012) mTOR signaling in growth control and disease. Cell 149, 274-293
5. Powers, R. W., 3rd, Kaeberlein, M., Caldwell, S. D., Kennedy, B. K., and Fields, S. (2006) Extension of chronological life span in yeast by decreased TOR pathway signaling. Genes Dev. 20, 174-184
6. Harrison, D. E., Strong, R., Sharp, Z. D., and Nelson., J. F., Astle, C. M., Flurkey, K., Nadon, N. L., and Wilkinson., J. E., Frenkel, K., Carter, C. S., Pahor, M., and Javors., M. A., Fernandez, E., and Miller, R. A. (2009) Rapamycin fed late in life extends lifespan in genetically heterogeneous mice. Nature 460, 392-395
7. Bjedov, I., and Toivonen., J. M., Kerr, F., Slack, C., Jacobson, J., Foley, A., and Partridge, L. (2010) Mechanismsoflife span extensionbyrapamycin inthe fruit fly Drosophila melanogaster. Cell Metab. 11, 35-46
8. Robida-Stubbs, S., Glover-Cutter, K., Lamming, D. W., Mizunuma, M., and Narasimhan., S. D., Neumann-Haefelin, E., Sabatini, D. M., and Blackwell, T. K. (2012) TOR signaling and rapamycin influence longevity by regulating SKN-1/Nrf and DAF-16/FoxO. Cell Metab. 15, 713-724
9. Sarbassov, D. D., and Ali., S. M., Kim, D. H., Guertin, D. A., and Latek., R. R., Erdjument-Bromage, H., Tempst, P., and Sabatini, D. M. (2004) Rictor, a novel binding partner of mTOR, defines a rapamycin-insensitive and raptor-independent pathway that regulates the cytoskeleton. Curr. Biol. 14, 1296-1302
10. Hara, K., Maruki, Y., Long, X., Yoshino, K., Oshiro, N., Hidayat, S., Tokunaga, C., Avruch, J., and Yonezawa, K. (2002) Raptor, a binding partner of target of rapamycin (TOR), mediates TOR action. Cell 110, 177-189
11. Inoki, K., Li, Y., Zhu, T., Wu, J., and Guan, K. L. (2002) TSC2 is phosphorylated and inhibited by Akt and suppresses mTOR signalling. Nat. Cell Biol. 4, 648-657
12. Ma, L., Chen, Z., Erdjument-Bromage, H., Tempst, P., and Pandolfi, P. P. (2005) Phosphorylation and functional inactivation of TSC2 by Erk implications for tuberous sclerosis and cancer pathogenesis. Cell 121, 179-193
13. Inoki, K., Ouyang, H., Zhu, T., Lindvall, C., Wang, Y., Zhang, X., Yang, Q., Bennett, C., Harada, Y., Stankunas, K., and Wang., C. Y., He, X., MacDougald, O. A., You, M., and Williams., B. O., and Guan, K. L. (2006) TSC2 integrates Wnt and energy signals via a coordinated phosphorylation by AMPK and GSK3 to regulate cell growth. Cell 126, 955-968
14. Garami, A., and Zwartkruis., F. J., Nobukuni, T., Joaquin, M., Roccio, M., Stocker, H., Kozma, S. C, Hafen, E., and Bos., J. L., and Thomas, G. (2003) Insulin activation of Rheb, a mediator of mTOR/S6K/4E-BP signaling, is inhibited by TSC1 and 2. Mol. Cell 11, 1457-1466
15. Inoki, K., Li, Y., Xu, T., and Guan, K. L. (2003) Rheb GTPase is a direct target of TSC2 GAP activity and regulates mTOR signaling. Genes Dev. 17, 1829-1834
16. Masui, K., and Cavenee., W. K., and Mischel, P. S. (2014) mTORC2 in the center of cancer metabolic reprogramming. Trends Endocrinol. Metab. 25, 364-373
17. Sarbassov, D. D., and Guertin., D. A., Ali, S. M., and Sabatini, D. M. (2005) Phosphorylation and regulation of Akt/PKB by the rictor-mTOR complex. Science 307, 1098-1101
18. García-Martínez, J. M., and Alessi, D. R. (2008) mTOR complex 2 (mTORC2) controls hydrophobic motif phosphorylation and activation of serum- and glucocorticoid-induced protein kinase 1 (SGK1). Biochem. J. 416, 375-385
19. Pause, A., and Belsham., G. J., Gingras, A. C., Donzé, O., Lin, T. A., and Lawrence., J. C., Jr., and Sonenberg, N. (1994) Insulin-dependent stimulation of protein synthesis by phosphorylation of a regulator of 5'-cap function. Nature 371, 762-767
20. Sonenberg, N, and Rupprecht., K. M., Hecht, S. M., and Shatkin, A. J. (1979) Eukaryotic mRNA cap binding protein: purification by affinity chromatography on Sepharose-coupled m7GDP. Proc. Natl. Acad. Sci. U.S.A. 76, 4345-4349
21. Gingras, A. C., Raught, B., and Sonenberg, N. (1999) eIF4 initiation factors: effectors of mRNA recruitment to ribosomes and regulators of translation. Annu. Rev. Biochem. 68, 913-963
22. Gingras, A. C., Raught, B., Gygi, S. P., Niedzwiecka, A., Miron, M., Burley, S. K., and Polakiewicz., R. D., Wyslouch-Cieszynska, A., Aebersold, R., and Sonenberg, N. (2001) Hierarchical phosphorylation of the translation inhibitor 4E-BP1. Genes Dev. 15, 2852-2864
23. Pons, B., Armengol, G., Livingstone, M., López, L., Coch, L., Sonenberg, N., and Ramón y Cajal, S. (2012) Association between LRRK2 and 4E-BP1 protein levels in normal and malignant cells. Oncol. Rep. 27, 225-231
24. Ali, S. M., and Sabatini, D. M. (2005) Structure of S6 kinase 1 determines whether raptor-mTOR or rictor-mTOR phosphorylates its hydrophobic motif site. J. Biol. Chem. 280, 19445-19448
25. Pullen, N, and Dennis., P. B., Andjelkovic, M., Dufner, A., Kozma, S. C., and Hemmings., B. A., and Thomas, G. (1998) Phosphorylation and activation of p70s6k by PDK1. Science 279, 707-710
26. Shin, S., Wolgamott, L., Yu, Y., Blenis, J., and Yoon, S. O. (2011) Glycogen synthase kinase (GSK)-3 promotes p70 ribosomal protein S6 kinase (p70S6K) activity and cell proliferation. Proc. Natl. Acad. Sci. U.S.A. 108, E1204-1213
27. S6k. EMBO J. 16, 3693-3704
28. Hosokawa, N, Hara, T., Kaizuka, T., Kishi, C., Takamura, A., Miura, Y., Iemura, S., Natsume, T., Takehana, K., Yamada, N, and Guan., J. L., Oshiro, N, and Mizushima, N (2009) Nutrient-dependent mTORC1 association with the ULK1-Atg13-FIP200 complex required for autophagy. Mol. Biol. Cell 20, 1981-1991
29. Jung, C. H., and Jun., C. B., Ro, S. H., Kim, Y. M., Otto, N M., Cao, J., Kundu, M., and Kim, D. H. (2009) ULK-Atg13-FIP200 complexes mediate mTOR signaling to the autophagy machinery. Mol. Biol. Cell 20, 1992-2003
30. Hara, T., Takamura, A., Kishi, C., Iemura, S., Natsume, T., Guan, J. L., and Mizushima, N. (2008) FIP200, a ULK-interacting protein, is required for autophagosome formation in mammalian cells. J. Cell Biol. 181, 497-510
31. He, C., and Klionsky, D. J. (2009) Regulation mechanisms and signaling pathways of autophagy. Annu. Rev. Genet. 43, 67-93
32. Chiu, M. I., Katz, H., and Berlin, V. (1994) RAPT1, a mammalian homolog of yeast Tor, interacts with the FKBP12/rapamycin complex. Proc. Natl. Acad. Sci. U.S.A. 91, 12574-12578
33. Sarbassov, D. D., and Ali., S. M., Sengupta, S., Sheen, J. H., and Hsu., P. P., Bagley, A. F., Markhard, A. L., and Sabatini, D. M. (2006) Prolonged rapamycin treatment inhibits mTORC2 assembly and Akt/PKB. Mol. Cell 22, 159-168
34. Edinger, A. L., and Linardic., C. M., Chiang, G.G., Thompson, C. B., and Abraham, R. T. (2003) Differential effects of rapamycin on mammalian target of rapamycin signaling functions in mammalian cells. Cancer Res. 63, 8451-8460
35. Thoreen, C. C., and Kang., S. A., Chang, J. W., Liu, Q., Zhang, J., Gao, Y., Reichling, L. J., Sim, T., and Sabatini., D. M., and Gray, N. S. (2009) An ATP-competitive mammalian target of rapamycin inhibitor reveals rapamycin-resistant functions of mTORC1. J. Biol. Chem. 284, 8023-8032
36. S6k inactivation is a novel phosphorylation site within a conserved hydrophobic domain. EMBO J. 14, 5279-5287
37. Livingstone, M., and Bidinosti, M. (2012) Rapamycin-insensitive mTORC1 activity controls eIF4E:4E-BP1 binding. F1000Research 1, 4
38. Dowling, R. J., Topisirovic, I., Alain, T., Bidinosti, M., and Fonseca., B. D., Petroulakis, E., Wang, X., Larsson, O., Selvaraj, A., Liu, Y., Kozma, S. C, Thomas, G., and Sonenberg, N. (2010) mTORC1-mediated cell proliferation, but not cell growth, controlled by the 4E-BPs. Science 328, 1172-1176
39. Zaytseva, Y. Y., Valentino, J.D., Gulhati, P., and Evers, B.M. (2012) mTOR inhibitors in cancer therapy. Cancer Lett. 319, 1-7
40. Long, M. J., and Gollapalli., D. R., and Hedstrom, L. (2012) Inhibitor mediated protein degradation. Chem. Biol. 19, 629-637
41. Schneider, C. A., and Rasband., W. S., and Eliceiri, K. W. (2012) NIH Image to ImageJ: 25 years of image analysis. Nat Methods 9, 671-675
42. Martinez Molina, D., Jafari, R., Ignatushchenko, M., Seki, T., Larsson, E. A., Dan, C, Sreekumar, L., Cao, Y., and Nordlund, P. (2013) Monitoring drug target engagement in cells and tissues using the cellular thermal shift assay. Science 341, 84-87
43. Alley, M. C, Scudiero, D. A., Monks, A., and Hursey., M. L., Czerwinski, M. J., Fine, D. L., and Abbott., B. J., Mayo, J. G., Shoemaker, R. H., and Boyd, M. R. (1988) Feasibility of drug screening with panels of human tumor cell lines using a microculture tetrazolium assay. Cancer Res. 48, 589-601
44. Thorne, N, Shen, M., Lea, W. A., Simeonov, A., Lovell, S., Auld, D. S., and Inglese, J. (2012) Firefly luciferase in chemical biology: a compendium of inhibitors, mechanistic evaluation of chemotypes, and suggested use as a reporter. Chem. Biol. 19, 1060-1072
45. Deroo, B. J., and Archer, T. K. (2002) Proteasome inhibitors reduce luciferase and β-galactosidase activity in tissue culture cells. J. Biol. Chem. 277, 20120-20123
46. Harding, H. P., Zhang, Y., Bertolotti, A., Zeng, H, and Ron, D. (2000) Perk is essential for translational regulation and cell survival during the unfolded protein response. Mol. Cell 5, 897-904
47. Dever, T. E., Feng, L., Wek, R. C, Cigan, A. M., and Donahue., T. F., and Hinnebusch, A. G. (1992) Phosphorylation of initiation factor 2a by protein kinase GCN2 mediates gene-specific translational control of GCN4 in yeast. Cell 68, 585-596
48. Oslowski, C. M., and Urano, F. (2011) Measuring ER stress and the unfolded protein response using mammalian tissue culture system. Methods Enzymol. 490, 71-92
49. Choo, A. Y., and Yoon., S. O., Kim, S. G., Roux, P. P., and Blenis, J. (2008) Rapamycin differentially inhibits S6Ks and 4E-BP1 to mediate cell-type-specific repression of mRNA translation. Proc. Natl. Acad. Sci. U.S.A. 105, 17414-17419
50. Chiang, G. G., and Abraham, R. T. (2005) Phosphorylation of mammalian target of rapamycin (mTOR) at Ser-2448 is mediated by p70 S6 kinase. J. Biol. Chem. 280, 25485-25490
51. Thoreen, C C, Chantranupong, L., Keys, H. R., Wang, T., Gray, N. S., and Sabatini, D. M. (2012) A unifying model for mTORC1-mediated regulation of mRNA translation. Nature 485, 109-113
52. Kabeya, Y., Mizushima, N, Ueno, T., Yamamoto, A., Kirisako, T., Noda, T., Kominami, E., Ohsumi, Y., and Yoshimori, T. (2000) LC3, a mammalian homologue of yeast Apg8p, is localized in autophagosome membranes after processing. EMBO J. 19, 5720-5728
53. Copp, J., Manning, G., and Hunter, T. (2009) TORC-specific phosphorylation of mammalian target of rapamycin (mTOR): phospho-Ser2481 is a marker for intact mTOR signaling complex 2. Cancer Res. 69, 1821-1827
54. Wu, S., Mikhailov, A., Kallo-Hosein, H, Hara, K., Yonezawa, K., and Avruch, J. (2002) Characterization of ubiquilin 1, an mTOR-interacting protein. Biochim. Biophys. Acta 1542, 41-56
55. Teilum, K., and Olsen., J. G., and Kragelund, B. B. (2011) Protein stability, flexibility and function. Biochim. Biophys. Acta 1814, 969-976
56. Su, V., and Lau, A. F. (2009) Ubiquitin-like and ubiquitin-associated domain proteins: significance in proteasomal degradation. Cell Mol. Life Sci. 66, 2819-2833
57. Abraham, R. T., and Wiederrecht, G. J. (1996) Immunopharmacology of rapamycin. Annu. Rev. Immunol. 14, 483-510
58. Lekmine, F., Uddin, S., Sassano, A., Parmar, S., and Brachmann., S. M., Majchrzak, B., Sonenberg, N, Hay, N, Fish, E. N, and Platanias, L. C (2003) Activation of the p70 S6 kinase and phosphorylation of the 4E-BP1 repressor of mRNA translation by type I interferons. J. Biol. Chem. 278, 27772-27780
59. Kleijnen, M. F., and Shih., A. H., Zhou, P., Kumar, S., Soccio, R. E., and Kedersha., N. L., Gill, G., and Howley, P. M. (2000) The hPLIC proteins may provide a link between the ubiquitination machinery and the proteasome. Mol. Cell 6, 409-419
60. Zhang, D., Raasi, S., and Fushman, D. (2008) Affinity makes the difference: nonselective interaction of the UBA domain of Ubiquilin-1 with monomeric ubiquitin and polyubiquitin chains. J. Mol. Biol. 377, 162-180
61. Raasi, S., Varadan, R., Fushman, D., and Pickart, C. M. (2005) Diverse polyubiquitin interaction properties of ubiquitin-associated domains. Nat. Struct. Mol. Biol. 12, 708-714
62. Safren, N, El Ayadi, A., Chang, L., Terrillion, C. E., and Gould., T. D., Boehning, D. F., and Monteiro, M. J. (2014) Ubiquilin-1 overexpression increases the lifespan and delays accumulation of Huntingtin aggregates in the R6/2 mouse model of Huntington's disease. PLoS ONE 9, e87513
63. Bertram, L., Hiltunen, M., Parkinson, M., Ingelsson, M., Lange, C, Ramasamy, K., Mullin, K., Menon, R., and Sampson., A. J., Hsiao, M. Y., Elliott, K. J., Velicelebi, G., Moscarillo, T., Hyman, B. T., and Wagner., S. L., Becker, K. D., Blacker, D., and Tanzi, R. E. (2005) Family-based association between Alzheimer's disease and variants in UBQLN1. N Engl. J. Med. 352, 884-894
64. Deng, H. X., Chen, W., Hong, S. T., and Boycott., K. M., Gorrie, G. H., Siddique, N., Yang, Y., Fecto, F., Shi, Y., Zhai, H., Jiang, H., Hirano, M., Rampersaud, E., and Jansen., G. H., Donkervoort, S., Bigio, E. H., and Brooks., B. R., Ajroud, K., Sufit, R. L., Haines, J. L., Mugnaini, E., Pericak-Vance, M. A., and Siddique, T. (2011) Mutations in UBQLN2 cause dominant X-linked juvenile and adult-onset ALS and ALS/dementia. Nature 477, 211-215
65. Davidson, J. D., Riley, B., Burright, E. N., and Duvick., L. A., Zoghbi, H. Y., and Orr, H. T. (2000) Identification and characterization of an ataxin-1-inter-acting protein: A1Up, a ubiquitin-like nuclear protein. Hum. Mol. Genet. 9, 2305-2312
66. N'Diaye, E. N., Kajihara, K. K., Hsieh, I., Morisaki, H., Debnath, J., and Brown, E. J. (2009) PLIC proteins or ubiquilins regulate autophagy-dependent cell survival during nutrient starvation. EMBO Rep. 10, 173-179
67. Rothenberg, C, Srinivasan, D., Mah, L., Kaushik, S., and Peterhoff., C. M., Ugolino, J., Fang, S., Cuervo, A. M., and Nixon., R. A., and Monteiro, M. J. (2010) Ubiquilin functions in autophagy and is degraded by chaperone-mediated autophagy. Hum. Mol. Genet. 19, 3219-3232
68. Lee, D. Y., Arnott, D., and Brown, E. J. (2013) Ubiquilin4 is an adaptor protein that recruits Ubiquilin1 to the autophagy machinery. EMBO Rep. 14, 373-381
69. Bové, J., Martínez-Vicente, M., and Vila, M. (2011) Fighting neurodegen-eration with rapamycin: mechanistic insights. Nat. Rev. Neurosci. 12, 437-452
70. Kapahi, P., Chen, D., Rogers, A. N, Katewa, S. D., and Li., P. W., Thomas, E. L., and Kockel, L. (2010) With TOR, less is more: a key role for the conserved nutrient-sensing TOR pathway in aging. CellMetab. 11, 453-465
71. Houghton, P. J., and Morton., C. L., Gorlick, R., Lock, R. B., Carol, H, and Reynolds., C. P., Kang, M. H., Maris, J. M., and Keir., S. T., Kolb, E. A., Wu, J., Wozniak, A. W., and Billups., C. A., Rubinstein, L., and Smith, M. A. (2010) Stage 2 combination testing of rapamycin with cytotoxic agents by the Pediatric Preclinical Testing Program. Mol. Cancer Ther. 9, 101-112
72. Tain, L. S., Mortiboys, H, Tao, R. N, Ziviani, E., Bandmann, O., and Whitworth, A. J. (2009) Rapamycin activation of 4E-BP prevents parkinsonian dopaminergic neuron loss. Nat Neurosci. 12, 1129-1135